PCI 3.06.26
Wallonia

Current Edition

Current Features

Biomanufacturing

Mastering ADC Bioconjugation: From DAR Control to Efficient Free Payload Removal

Continue reading

Upcoming Events

Auto Draft
CPHI
Bioprocessing summit
DDL 2026
Biotechnology Show 13.02.26

Advertisement

Advertisement

A&M Stabtest April 26

Advertisement

Biopharma Group – 19th March 2025

Advertisement

Micron View
news

Two cancer cell therapy studies succeeded. Why did a third fail?

In two major clinical trials, researchers found cell therapy dramatically outperformed the standard of care used for the past few decades to counter a common type of ...
Continue Reading →
news

As FDA scrutinizes immunotherapy approvals, Merck says Keytruda extends survival in liver cancer trial

The FDA has been under pressure to review the status of drugs granted accelerated approvals based on early data, as in some cases confirmatory trials haven't been com...
Continue Reading →
news

Roche bets big on off-the-shelf cancer cell therapy with Adaptimmune deal

Adaptimmune, like companies such as Bluebird Bio and Cellectis, remains one of the more prominent independent developers of cancer cell therapies. Early pioneers Kite...
Continue Reading →
news

GSK, in race to catch up with rivals, wins expanded approval for cancer drug

GSK has high hopes for Jemperli as it transitions to what's being called the "new GSK," with a greater focus on experimental drugs for infectious disease, cancer and ...
Continue Reading →
news

Regeneron drug extends survival in lung cancer trial, lifting company’s hopes in field

Since its first approval in first-line lung cancer in 2016, Keytruda has proved a tough competitor for rival drugmakers to challenge with their own therapies. Bristol...
Continue Reading →

Advertisement

Richter: Wed 23 October 2024, 09:03

Advertisement

Aseptic Tech

Advertisement

Steribar – 12.05.2025

Advertisement

PharmExcel

Advertisement

Polypure hompage

Advertisement

Gen Xpro

Advertisement

Alphinity